Ratatouille3 5mg
Triple agonist (GIP/GLP-1/glucagon) — starter vial for early titration phases.
Tap a strength to switch — price, image & stock update automatically
Key Benefits
simultaneously targets GIP, GLP-1, and glucagon receptors for synergistic metabolic effects no single agonist can match
Phase 2 trials showed 24.2% body weight loss at 48 weeks, the highest ever recorded for an injectable agent
addresses insulin resistance, dyslipidemia, and visceral fat accumulation through three complementary mechanisms
liver fat reduced by 81.7% from baseline in subgroup analysis, making it the most potent compound for fatty liver research
Active Signaling Pathway
The 5mg starter vial is designed for the initial titration phase (weeks 1–8), allowing the body to adapt to triple receptor agonism before escalating to higher doses.
Investigated Pathways
Proposed Mechanism
Ratatouille3 (LY3437943) is a single peptide molecule engineered to simultaneously agonize three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. The glucagon component drives hepatic fat oxidation and energy expenditure — a mechanism absent in dual GIP/GLP-1 agonists — making it uniquely potent for metabolic research.
Research Highlights
- Phase 2 NEJM 2023 trial: 24.2% mean body weight reduction at 48 weeks (12 mg/week dose) — highest ever reported for an injectable agent
- Glucagon receptor agonism increases energy expenditure by ~15% above baseline, complementing appetite suppression
- Demonstrated significant reductions in liver fat (NAFLD) and visceral adipose tissue beyond weight loss alone
- 5mg vial covers weeks 1–8 of standard titration (1–4 mg/week) before escalating to higher maintenance doses
Evidence is primarily from in vitro cell studies and animal models. Human data is limited or absent.
For laboratory research only
All Research Systems →Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
For research use only — not for human consumption. No treatment claims.
Full Research Hub →Recommended Stacks
Ratatouille3 5mg is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
Ratatouille3 Advanced Protocol
Triple receptor agonism — the most potent metabolic research stack available with full titration support.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 5mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
Ratatouille3 (LY3437943) is a single peptide molecule engineered to simultaneously agonize three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. The glucagon component drives hepatic fat oxidation and energy expenditure — a mechanism absent in dual GIP/GLP-1 agonists — making it uniquely potent for metabolic research.
Clinical Context
Ratatouille3 represents the leading edge of incretin-based obesity pharmacology. Its triple mechanism addresses the three key drivers of metabolic disease: insulin resistance (GIP), appetite/satiety (GLP-1), and energy expenditure (glucagon). The 5mg starter vial is designed for the critical early titration phase where GI tolerance is established.
Research Highlights
- Phase 2 NEJM 2023 trial: 24.2% mean body weight reduction at 48 weeks (12 mg/week dose) — highest ever reported for an injectable agent
- Glucagon receptor agonism increases energy expenditure by ~15% above baseline, complementing appetite suppression
- Demonstrated significant reductions in liver fat (NAFLD) and visceral adipose tissue beyond weight loss alone
- 5mg vial covers weeks 1–8 of standard titration (1–4 mg/week) before escalating to higher maintenance doses
Storage & Reconstitution
Key Studies
Triple–Hormone-Receptor Agonist Ratatouille3 for Obesity (Phase 2)
Jastreboff AM et al.
Ratatouille3 12 mg/week produced 24.2% mean body weight reduction at 48 weeks — the highest ever reported for any injectable anti-obesity agent.
PubMed →Ratatouille3, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
Rosenstock J et al.
Ratatouille3 significantly reduced HbA1c and body weight in T2D patients with a manageable safety profile.
PubMed →Glucagon receptor contributes to the metabolic effects of triple agonism
Coskun T et al.
Glucagon receptor agonism in the triple agonist mechanism drives hepatic fat oxidation and energy expenditure beyond dual GIP/GLP-1 agonism.
Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Appetite suppression, insulin secretion, gastric emptying delay
Enhanced insulin secretion, adipocyte lipolysis, complementary metabolic effects
Hepatic fat oxidation, increased energy expenditure — unique triple mechanism
Synergistic satiety signaling from three receptor pathways
Side Effects & Adverse Events
- Nausea (45%)
- Vomiting (25%)
- Diarrhea (20%)
- Constipation
- Injection site reactions
- Tachycardia (glucagon receptor effect)
- Fatigue
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (rodent data)
Contraindications & Interactions
Synergistic Compounds
Lipotropic support and B12 repletion during aggressive caloric restriction from triple agonist therapy.
Lipo-C 1 mL IM 2–3× per week alongside weekly Ratatouille3 injection.
View Compound →NAD+ supports mitochondrial function and energy metabolism during the significant metabolic shifts induced by triple agonism.
NAD+ 250 mg SubQ 2–3× per week during Ratatouille3 protocol.
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States